Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
| ▸ | GRM5 | P41594 | 3/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14097932 | 1.00 | POLB (0.43) | POLBGPR119GRM5GRM1MAPK1 | |
| SCHEMBL17094798 | 0.99 | POLB (0.42) | POLBGPR119GRM5GRM1MAPK1 | |
| SCHEMBL18181042 | 0.90 | POLB (0.40) | POLBGPR119GRM5GRM1MAPK1 | |
| SCHEMBL17094785 | 0.90 | POLB (0.41) | POLBGPR119GRM5GRM1MAPK1 | |
| Lithium Ion SCHEMBL17094797 | 0.89 | POLB (0.40) | POLBGPR119GRM5GRM1MAPK1 | |
| SCHEMBL17094830 | 0.89 | PTPN1 (0.42) | POLBGPR119GRM5GRM1MAPK1 | |
| SCHEMBL4597401 | 0.86 | NR1D1 (0.40) | POLBGPR119GRM5GRM1 | |
| SCHEMBL8877460 | 0.85 | POLB (0.43) | POLBGPR119GRM5GRM1MAPK1 | |
| SCHEMBL18181191 | 0.85 | POLB (0.43) | POLBGPR119GRM5GRM1MAPK1 | |
| SCHEMBL17094786 | 0.85 | CHIA (0.41) | POLBGPR119MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417144-B2 | e.g. 1-Methyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-4,5-dicarboxylic acid 5-[(4-chloro-phenyl)-amide]4-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide}; anticoagulant, antiinflammatory agent; thrombosis, peripheral arterial occlusive disease, stroke, arteriosclerosis, bypass grafting | HOFFMAN-LA ROCHE INC. (US) | 2008-08-26 | — | — | US | disclosed |
| EP-1907388-A1 | NOVEL HETEROARYL FUSED CYCLIC AMINES | F. Hoffmann-Roche AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007009883-A1 | NOVEL HETEROARYL FUSED CYCLIC AMINES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| US-20070015812-A1 | Factor Xa inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015812-A1 | Factor Xa inhibitors | F12, F11, F2 | POLB 3801/4885GPR119 2863/4885GRM5 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.